Innovative go-to-market strategy for a large European pharmaceutical company.
With decreasing pipelines, increasing treatment costs, higher competition, and stricter and changing regulations, it has become imperative for life sciences to think of innovative commercial operations models to achieve success/make products successful. Despite the supply of real-time digital information, a hefty percentage of healthcare professionals (HCPs) still prefer personal interactions with a sales rep compared to the other channel. That preference for meeting the sales rep runs more profound the longer an HCP and a Rep have a working understanding and when their interaction is predicated on a common goal to enhance patient outcomes.
It is not that the life sciences companies weren't embracing the multichannel approach, but the COVID-19 pandemic has acted as a catalyst and has changed the scenarios rapidly. An omnichannel strategy is becoming necessary to interact with all HCPs and capture the share of mind.
Axtria brought its deep expertise in omnichannel call planning, commercial analytics, and operations to help a large European life sciences organization transform its go-to-market strategy.
Read this illustration to know how Axtria engaged with a European life science major and helped develop an innovative omnichannel call planning that improved the reps' engagement with the HCPs and, therefore, targeting effectiveness.
Contact us at firstname.lastname@example.org with any questions.